Research Paper Volume 13, Issue 13 pp 17407—17427

Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways

MBZ and cisplatin synergistically inhibit tumor growth in the xenograft tumor model of human CR ovarian cancer cells. Exponentially growing SKOV3CR cells were collected and subcutaneously injected into the flanks of athymic nude mice (n = 6 per group). At 7 days post injection, the mice were randomly divided into four groups, and treated with DMSO, MBZ, and/or Cisplatin (Cis) for three weeks. Tumor growth was monitored and average tumor growth was calculated. (A) Representative retrieved tumor masses were photographed individually (B-a) or pooled in Eppendorf tubes. (B-b) The retrieved tumor masses were subjected to H & E staining (C-a), and anti-PCNA immunochemical staining (C-b). Minus primary antibody and control IgG were used as negative controls. Representative results are shown.

Figure 6. MBZ and cisplatin synergistically inhibit tumor growth in the xenograft tumor model of human CR ovarian cancer cells. Exponentially growing SKOV3CR cells were collected and subcutaneously injected into the flanks of athymic nude mice (n = 6 per group). At 7 days post injection, the mice were randomly divided into four groups, and treated with DMSO, MBZ, and/or Cisplatin (Cis) for three weeks. Tumor growth was monitored and average tumor growth was calculated. (A) Representative retrieved tumor masses were photographed individually (B-a) or pooled in Eppendorf tubes. (B-b) The retrieved tumor masses were subjected to H & E staining (C-a), and anti-PCNA immunochemical staining (C-b). Minus primary antibody and control IgG were used as negative controls. Representative results are shown.